This discussion is part of a series titled "When to start using SGLT2i in HFrEF? Initiating guideline-recommended treatment options".
When to start using SGLT2i in HFrEF? Initiating guideline-recommended treatment options
Be part of the knowledge.™Register
We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?
When to start using SGLT2i in HFrEF? Initiating guideline-recommended treatment options
Restart
Resume
Transcript
When to start using SGLT2i in HFrEF? Initiating guideline-recommended treatment options
closeShare this program on:
Choose a format
Media formats available:
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Details
Presenters
Comments
Overview
Educational information
This discussion is part of a series titled "When to start using SGLT2i in HFrEF? Initiating guideline-recommended treatment options".
Faculty
Prof. John McMurray, MD (Glasgow, UK), Prof. Carolyn Lam, MD, PhD (Singapore), and Prof. Scott Solomon, MD (Boston, MA, USA)
Disclosures
This recording was independently developed under auspices of PACE-cme. The views expressed in this recording are those of the individual presenter and do not necessarily reflect the views of PACE-cme.
Funding
Funding for this educational program was provided by an unrestricted educational grant from AstraZeneca.
Presenters
Recommended
Details
Presenters
Comments
Recommended
Overview
This discussion is part of a series titled "When to start using SGLT2i in HFrEF? Initiating guideline-recommended treatment options".
Educational information
This discussion is part of a series titled "When to start using SGLT2i in HFrEF? Initiating guideline-recommended treatment options".
Faculty
Prof. John McMurray, MD (Glasgow, UK), Prof. Carolyn Lam, MD, PhD (Singapore), and Prof. Scott Solomon, MD (Boston, MA, USA)
Disclosures
This recording was independently developed under auspices of PACE-cme. The views expressed in this recording are those of the individual presenter and do not necessarily reflect the views of PACE-cme.
Funding
Funding for this educational program was provided by an unrestricted educational grant from AstraZeneca.
Presenters
Facebook Comments